2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC)
MUSTAFA, OZGUROGLU/0000-0002-8417-8628WOS: 000496473200760[No abstract available]Merck KGaA, Darmstadt, Germany; Pfizer Inc., New York, NY, USAPfizerThis study was funded by Merck KGaA, Darmstadt, Germany, as part of an alliance between Merck KGaA, Darmstadt, Germany and Pfizer Inc., New York, NY, USA
